DCPH Overzicht aandelen
A biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Deciphera Pharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$25.59 |
| 52 Week Hoogtepunt | US$25.61 |
| 52 Week Laag | US$9.90 |
| Bèta | 0.18 |
| 11 maand verandering | 0.91% |
| 3 maanden verandering | 60.14% |
| 1 Jaar Verandering | 76.48% |
| 33 jaar verandering | -28.68% |
| 5 jaar verandering | 6.71% |
| Verandering sinds IPO | 44.99% |
Recent nieuws en updates
Recent updates
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up
Apr 30
Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Rendement voor aandeelhouders
| DCPH | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.08% | -0.7% | -1.6% |
| 1Y | 76.5% | 19.8% | 30.8% |
Rendement versus industrie: DCPH exceeded the US Biotechs industry which returned 6.8% over the past year.
Rendement versus markt: DCPH exceeded the US Market which returned 20.8% over the past year.
Prijsvolatiliteit
| DCPH volatility | |
|---|---|
| DCPH Average Weekly Movement | 20.9% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: DCPH's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: DCPH's weekly volatility has increased from 12% to 21% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2003 | 355 | Steve Hoerter | www.deciphera.com |
Deciphera Pharmaceuticals, Inc. Samenvatting
| DCPH fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.21b |
| Inkomsten(TTM) | -US$190.42m |
| Inkomsten(TTM) | US$174.91m |
12.7x
P/S-verhouding-11.6x
Koers/WinstverhoudingIs DCPH overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| DCPH resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$174.91m |
| Kosten van inkomsten | US$242.52m |
| Brutowinst | -US$67.61m |
| Overige uitgaven | US$122.80m |
| Inkomsten | -US$190.42m |
Laatst gerapporteerde inkomsten
Mar 31, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -2.20 |
| Brutomarge | -38.66% |
| Nettowinstmarge | -108.87% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde DCPH op de lange termijn?
Bekijk historische prestaties en vergelijking